Trulieve Cannabis (TRLV) has drawn fresh investor attention after celebrating Georgia’s expanded medical cannabis program with its first product sales in Marietta, while also reshaping its finance leadership and trading on the New York Stock Exchange.

Despite the Georgia rollout and NYSE listing increasing visibility, Trulieve Cannabis’ share price has been choppy, with a 30 day share price return down 12.47%, a 90 day share price return up 32.77%, and a 1 year total shareholder return of 111%.

If this kind of regulatory and product driven story interests you, it may be worth looking at other companies exposed to similar themes via our 40 healthcare AI stocks

After Trulieve Cannabis’ sharp swings and fresh NYSE spotlight, the gap between its recent US$8.63 share price and published fair value estimates is hard to ignore. How does that spread stack up against the valuation work behind it?

Most Popular Narrative: 55.6% Undervalued

With Trulieve Cannabis last closing at $8.63 against a narrative fair value of about $19.42, the current pricing gap is tied closely to expectations around federal tax relief, medical program expansion and long term profitability.

Federal reclassification of medical marijuana to Schedule III, along with the ability to register with the DEA and deduct ordinary expenses, is expected to reduce the impact of 280E and could free up more cash to support earnings and operating margins over time.

Want to see how Trulieve Cannabis gets from current losses to a rich earnings profile with a lower future earnings multiple than its industry peers? The narrative leans heavily on profit margin expansion, a shrinking revenue base and a specific discount rate to justify that higher fair value. Curious which mix of earnings, tax relief and valuation assumptions needs to line up for the model to work?

Result: Fair Value of $19.42 (UNDERVALUED)

However, the Trulieve Cannabis story also leans heavily on uncertain federal tax relief and regulatory expansion, and ongoing pricing pressure could still weigh on margins and cash generation.

Next Steps

With both risks and rewards in play around Trulieve Cannabis, do you want to move quickly and test the story against the underlying data yourself? Start by weighing the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Trulieve Cannabis?

If you are serious about building a stronger portfolio, do not stop with Trulieve Cannabis. Use the Simply Wall Street Screener to uncover fresh stock ideas tailored to your goals.

• Target potential upside in smaller companies that pass strict financial filters with a focused set of 20 elite penny stocks with strong financials.
• Zero in on companies that combine quality and attractive pricing by scanning our 45 high quality undervalued stocks.
• Strengthen your portfolio’s foundation by reviewing companies highlighted in the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.